---
schema_version: "secwatch.filing_event.v1"
accession: "0001636282-26-000051"
form_type: "8-K"
ticker: "SYRE"
cik: "0001636282"
company_name: "Spyre Therapeutics, Inc."
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:24:22.714697+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Spyre Q1 net loss $69M; SPY001 hits primary endpoint; cash runway to H2 2029

## Summary
- Net loss of $69.0M in Q1 2026 vs $44.8M in Q1 2025; R&D expenses $60.4M (up from $41.6M).
- Pro forma cash $1,176.8M as of March 31, 2026, including $435.3M net from April 2026 offering; runway into H2 2029.
- SPY001 achieved primary endpoint in Part A of SKYLINE: RHI score reduction 9.2 points (p<0.0001); clinical remission 40%, endoscopic improvement 51%.
- SPY001 safety consistent with α4β7 class; RA sub-study of SKYWAY over-enrolled, topline readout accelerated to Q3 2026.
- On track for 6 proof-of-concept readouts in 2026 across SKYLINE and SKYWAY Phase 2 trials.

## SEC filing metadata
- accession: 0001636282-26-000051
- form_type: 8-K
- ticker: SYRE
- cik: 0001636282
- company_name: Spyre Therapeutics, Inc.
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636282/000163628226000051/0001636282-26-000051-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636282/000163628226000051/syre-20260505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001636282-26-000051
- JSON: https://secwatch.observer/filing/0001636282-26-000051.json
- Plain text: https://secwatch.observer/filing/0001636282-26-000051.txt

## Source-grounded claims
- claim_id: 355ce8485407595f20dbf7a7c10dab4c5ca41cdb
  claim: Spyre Therapeutics, Inc. reported financial results for first quarter ended March 31, 2026.
  evidence_excerpt: On May 5, 2026, Spyre Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636282/000163628226000051/0001636282-26-000051-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.